Vaccine maker Adimmune Corp (國光生技) plans to conduct phase I clinical trials of its COVID-19 candidate vaccine next month to assess its safety, the firm said yesterday.
Adimmune expects to receive approval from the Food and Drug Administration (FDA) later this month to start trials, as the review has been going smoothly so far, Adimmune spokesman Pan Fei (潘飛) told the Taipei Times by telephone.
The vaccine provider would cooperate with National Taiwan University Hospital (NTUH) for the trials, Pan said.
The company plans to enroll 60 to 80 healthy adult participants, who would be divided into several groups and receive vaccines at different doses, to see if the experimental vaccine is safe, Pan said.
“We will monitor if there are any severe side effects to the participants and if they produce coronavirus antibodies. Based on the results of phase I trials, we will select two dose levels that show the most promise to continue with phase II clinical trials,” Pan said.
Although Minister of Health and Welfare Chen Shih-chung (陳時中) last week said that the government would allow biotechnology firms to skip phase III clinical trials of their vaccine candidates to accelerate vaccine development, Adimmune would not eschew the final phase of human trials, Pan said.
“We are considering combining phase II and phase III trials into a phase II/III design to save time and reduce the total number of test participants,” he said.
The firm still needs to discuss with the regulator the protocol for a phase II/III trial, including clinical endpoints and the number of enrolled participants, he added.
Adimmune, the nation’s largest flu vaccine provider, is a frontrunner in the local race to develop a COVID-19 vaccine, as it was the first to apply to the FDA to conduct human trials.
Its vaccine candidate, developed using the novel coronavirus’ genetic sequence and the firm’s recombinant protein technology, in an animal test in April caused laboratory mice to produce antibodies that could inhibit the growth of the coronavirus, company data showed.
The firm’s achievements have been rewarded by investors, with its stock price rising from NT$36.35 on May 6 — when it announced the results of its animal test — to NT$75.6 at the close of Taipei trading yesterday.
However, the company did not take advantage of its high stock price to raise capital, as it did not issue new common shares, but took out a NT$4.2 billion (US$142 million) syndicated loan from nine local banks to fuel research, new factories and international development.
“Taking the syndicated loan did not increase our financial burden thanks to lower interest rates while we did not want to expand the number of shares in the short term due to concerns over stock dilution,” Pan said.
Last week, Medigen Vaccine Biologics Corp (高端疫苗) applied to the FDA to run phase I human trials for its spike protein-based vaccine candidate, becoming second in the local race to produce a COVID-19 vaccine, company data showed.
Separately yesterday, Golden Biotechnology Corp (GBC, 國鼎生物科技) announced that it has gained approval from the US Food and Drug Administration to conduct phase II human trials for its small molecule drug, Antroquinonol (Hocena), as COVID-19 treatment, it said in a filing with the Taipei Exchange.
The drug, originally developed to treat pancreatic cancer, has proven safe in its phase I human trial in the US, the firm said.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last